The Prevalence of Antinuclear Antibodies in Patients with Sarcoidosis

Introduction. Sarcoidosis, which is a chronic inflammatory granulomatous disease, can mimic different rheumatologic diseases including connective tissue diseases. Antinuclear antibodies are the markers used for connective tissue diseases.Aim. To determine antinuclear antibody frequency and any possible correlation with clinical and laboratory data in sarcoidosis patients.Material and Method. Forty-two sarcoidosis patients, 45 rheumatoid arthritis patients, and 45 healthy volunteers who were followed up in rheumatology outpatient clinic were included in this study. Demographic, clinical, serological, and radiological data of all patients were recorded. Antinuclear antibodies were determined with indirect immunofluorescent method and 1/100 titration was accepted as positive. The cases that were ANA positive were evaluated with immunoblot method.Results. Average age of the 42 patients (10 males) with sarcoidosis was 45.2 (20–70 years), and average disease duration was 3.5 years. ANA positivity was detected in 12 (28.5%) patients with sarcoidosis (1/100 in 10 patients, 1/320 in two patients), in 19 of RA patients (42.2%), and in two of healthy volunteers in low titer (P<0.001). In the subgroup analysis made by immunblot test, one patient had anticentromere antibody, one had anti-Ro antibody, one had anti-Scl-70 antibody, one had anti-dsDNA antibody, and eight patients were negative. The two patients who had anticentromere and anti-Scl-70 antibodies had also Sjögren’s syndrome and scleroderma diagnosis, respectively.Discussion. The prevalence of ANA in patients with sarcoidosis was found to be significantly higher than healthy control group and lower than RA patients. This result shows that ANA may have an important role in the pathogenesis of sarcoidosis and also could be important in revealing the overlap syndromes of sarcoidosis-connective tissue diseases. Further studies with larger series are necessary in this subject.

Download Full-text

Evaluation of a Multiplex ELISA for Autoantibody Profiling in Patients with Autoimmune Connective Tissue Diseases

Autoimmune Diseases ◽

10.1155/2014/896787 ◽

2014 ◽

Vol 2014 ◽

pp. 1-6

Author(s):

Alejandro Caro Pérez ◽

Sarita Kumble ◽

Krishnanand D. Kumble ◽

M. Consuelo Alonso Cañizal ◽

Luis M. Jiménez Jiménez ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Connective Tissue ◽

Infectious Diseases ◽

Healthy Subjects ◽

Laboratory Data ◽

Connective Tissue Diseases ◽

Control Group ◽

Critical Importance ◽

Clinical Tool ◽

Cohen's Kappa

The performance of immunoassays for the detection of autoantibodies is of critical importance in the diagnosis and assessment of patients with autoimmune connective tissue diseases (ACTD). Our objective was to compare the features of two multiplexed assays—INNO-LIA ANA and Gennova-PictArray ENA ELISA—for measurement of multiple autoantibodies and their utility as a clinical tool in ACTD diagnosis. The antigens included SS-A/Ro (60 and 52), SSB/La, Sm, Sm/RNP, CENP-B, Jo-1, and Scl-70. Stored sera from 85 ACTD patients and 80 controls consisting of patients with vasculitis, rheumatoid arthritis and infectious diseases, as well as healthy subjects were analyzed jointly with clinical and laboratory data. Agreement between the two methods varied between 58 and 99% (Cohen’s kappa: 0.21–0.71) mostly for SSA and SSB. The frequency of specific autoantibodies measured using the two methods was more variable for SSA, SSB, and RNP/Sm. There were a higher number of ambiguous results when using INNO-LIA. The optimized cut-off values of the Gennova-PictArray resulted in over 99% specificities in samples obtained from the control group. Sensitivity patterns were more accurate in Gennova-PictArray than in INNO-LIA, as suggested in previously reported studies. A third method could be applied to determine which of the two methods is more accurate.

Download Full-text

Antinuclear Antibodies: Contemporary Techniques and Clinical Application to Connective Tissue Diseases.

Annals of Internal Medicine ◽

10.7326/0003-4819-101-6-893_2 ◽

1984 ◽

Vol 101 (6) ◽

pp. 893

Keyword(s):

Connective Tissue ◽

Clinical Application ◽

Antinuclear Antibodies ◽

Connective Tissue Diseases

Download Full-text

Serum KL-6 as predictive and prognostic marker of interstitial lung disease in childhood connective tissue diseases: a pilot study

Reumatismo ◽

10.4081/reumatismo.2021.1399 ◽

2021 ◽

Vol 73 (3) ◽

Author(s):

R. El-Beheidy ◽

A.M. Domouky ◽

H. Zidan ◽

Y.A. Amer

Keyword(s):

Interstitial Lung Disease ◽

Connective Tissue ◽

Lung Disease ◽

Lupus Erythematosus ◽

Connective Tissue Diseases ◽

Control Group ◽

Connective Tissue Disorders ◽

Juvenile Systemic Lupus Erythematosus ◽

Median Serum ◽

Juvenile Systemic Sclerosis

This study was aimed to evaluate serum KL-6 levels to determine if this marker can be used for diagnosing and assessing severity of interstitial lung disease (ILD) in children with connective tissue disorders. In total, 40 patients [18 patients with juvenile systemic lupus erythematosus (JSLE), 10 patients with juvenile idiopathic arthritis (JIA), 8 patients with juvenile mixed connective tissue disease (JMCTD), 3 patients with juvenile systemic sclerosis (JSSc), and 1 patient with juvenile dermatomyositis (JDM)] and 20 healthy controls were included in this study. Age, sex, and duration of CTD and ILD (if any) were recorded. Blood samples from all the patients and controls were examined by ELISA. 20 of the 40 patients with CTD (50%) had ILD, 12 were mild and 8 were severe as assessed by spirometry. The median serum KL-6 level was 102.7 U/mL (76.1-180.8) in the CTD with severe ILD group, 72.2 U/mL (58.4- 100.5) in the CTD with mild ILD group, 56.7 U/mL (35.8-68.5) in the CTD without ILD group, and 52.3 U/mL (32.8-62.4) in the control group. KL-6 levels were significantly higher in the CTD with ILD (p<0.05), at a cutoff of 63.4 U/ml identified by ROC curve, serum KL-6 showed a sensitivity of 95.2% and specificity of 89.7%. KL-6 is a valuable biomarker for diagnostic purposes and to detect severity in ILD in childhood CTD.

Download Full-text

Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: A study of one hundred thirty-three cases compared with a control group

Arthritis & Rheumatism ◽

10.1002/art.11304 ◽

2003 ◽

Vol 48 (11) ◽

pp. 3207-3211 ◽

Cited By ~ 200

Author(s):

Nathalie Costedoat-Chalumeau ◽

Zahir Amoura ◽

Pierre Duhaut ◽

Du Le Thi Huong ◽

Djamel Sebbough ◽

...

Keyword(s):

Connective Tissue ◽

Connective Tissue Diseases ◽

Control Group

Download Full-text

Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects with Normal or Impaired Hepatic Function

Antimicrobial Agents and Chemotherapy ◽

10.1128/aac.44.4.821-826.2000 ◽

2000 ◽

Vol 44 (4) ◽

pp. 821-826 ◽

Cited By ~ 55

Author(s):

Laurence Veronese ◽

Jacques Rautaureau ◽

Brian M. Sadler ◽

Catherine Gillotin ◽

Jean-Pierre Petite ◽

...

Keyword(s):

Liver Disease ◽

Healthy Volunteers ◽

Total Bilirubin ◽

Laboratory Data ◽

Hepatic Insufficiency ◽

Pharmacokinetic Parameters ◽

Control Group ◽

Bilirubin Concentration ◽

Total Bilirubin Concentration ◽

Severe Cirrhosis

ABSTRACT Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces P450-mediated metabolism, the concentrations in plasma of drugs metabolized through this pathway are often increased in subjects with liver disease. Following administration of a single, oral dose of 600 mg of amprenavir, pharmacokinetic parameters were determined for 10 subjects with severe cirrhosis, 10 subjects with moderate cirrhosis, and 10 healthy volunteers. Model-independent methods for determining the area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC0–∞) showed an increase in amprenavir AUC0–∞ of 2.5-fold in the group with moderate cirrhosis and 4.5-fold in the group with severe cirrhosis compared with that in the control group of healthy volunteers (P < 0.05). AUC0–∞ was linearly related to the severity of liver disease, as assessed by the Child-Pugh score. Of the laboratory data used to calculate the Child-Pugh score, only the mean total bilirubin concentration showed a significant relationship with AUC0–∞. The relationship between the total bilirubin concentration and the AUC0–∞ of amprenavir was well characterized by a simple E max model, suggesting that the total bilirubin concentration may be a useful parameter for predicting the amprenavir AUC in subjects with hepatic insufficiency. Finally, the sera of cirrhotic subjects showed significant decreases in the levels of α1-acid glycoprotein, the primary plasma binding protein for amprenavir. On the basis of the results of this study, for an exposure equivalent to a clinical dose of 1,200 mg twice daily in subjects without cirrhosis, subjects with Child-Pugh scores of 5 to 8 should receive a twice-daily 450-mg dose of amprenavir, and subjects with Child-Pugh scores of 9 to 15 should receive a twice-daily 300-mg dose of amprenavir.

Download Full-text

Staining of antinuclear antibodies and antibodies against removable nuclear antigens in connective tissue diseases

Allergologia et Immunopathologia ◽

10.1016/j.aller.2019.07.002 ◽

2020 ◽

Vol 48 (1) ◽

pp. 18-25

Author(s):

José Enrique Oliva Menacho ◽

Jorge Luis Arroyo-Acevedo ◽

José Arturo Oliva-Candela ◽

Marco Antonio García-Hjarles ◽

Lester Domínguez-Huarcaya

Keyword(s):

Connective Tissue ◽

Antinuclear Antibodies ◽

Connective Tissue Diseases ◽

Nuclear Antigens

Download Full-text

The Serum Cell-Free microRNA Expression Profile in MCTD, SLE, SSc, and RA Patients

Journal of Clinical Medicine ◽

10.3390/jcm9010161 ◽

2020 ◽

Vol 9 (1) ◽

pp. 161 ◽

Cited By ~ 6

Author(s):

Barbara Stypinska ◽

Anna Wajda ◽

Ewa Walczuk ◽

Marzena Olesinska ◽

Aleksandra Lewandowska ◽

...

Keyword(s):

Connective Tissue ◽

Signaling Pathway ◽

Expression Profile ◽

Mirna Expression ◽

Lupus Erythematosus ◽

Connective Tissue Diseases ◽

Mirna Expression Profile ◽

Expression Level ◽

Control Group ◽

Mirna Expression Level

Mixed connective tissue disease (MCTD) is a rare disorder characterized by symptoms that overlap two or more Autoimmune Connective Tissue Diseases (ACTDs). The aim of this study was to determine whether miRNAs participating in the TLRs signaling pathway could serve as biomarkers differentiating MCTD or other ACTD entities from a healthy control group and between groups of patients. Although the selected miRNA expression level was not significantly different between MCTD and control, we observed that miR-126 distinguishes MCTD patients from all other ACTD groups. The expression level of miRNAs was significantly higher in the serum of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients compared to controls. The miR-145 and -181a levels distinguished RA from other ACDT patients. miR-155 was specific for SLE patients. MiR-132, miR-143, and miR-29a distinguished RA and SLE patients from the systemic sclerosis (SSc) group. Additionally, some clinical parameters were significantly related to the miRNA expression profile in the SLE group. SLE and RA are characterized by a specific serum expression profile of the microRNAs associated with the Toll-like receptors (TLRs) signaling pathway. The analysis showed that their level distinguishes these groups from the control and from other ACTD patients. The present study did not reveal a good biomarker for MCTD patients.

Download Full-text

Detection of Antinuclear Antibodies by Use of an Enzyme Immunoassay with Nuclear HEp-2 Cell Extract and Recombinant Antigens: Comparison with Immunofluorescence Assay in 307 Patients

Clinical Chemistry ◽

10.1093/clinchem/47.9.1649 ◽

2001 ◽

Vol 47 (9) ◽

pp. 1649-1659 ◽

Cited By ~ 33

Author(s):

Nobuhide Hayashi ◽

Tomoko Kawamoto ◽

Masahiko Mukai ◽

Akio Morinobu ◽

Masahiro Koshiba ◽

...

Keyword(s):

Connective Tissue ◽

Enzyme Immunoassay ◽

Sensitivity And Specificity ◽

Lupus Erythematosus ◽

Antinuclear Antibodies ◽

Connective Tissue Diseases ◽

Cell Extract ◽

Healthy Individuals ◽

Cell Extracts ◽

Disease Specific

Abstract Background: A new enzyme immunoassay (EIA) for automated detection of antinuclear antibodies (ANAs) uses a mixture of HEp-2 cell extracts and multiple recombinant nuclear antigens immobilized on beads. We compared this EIA and an immunofluorescence (IF) assay in a large group of patients and controls. Methods: We studied 492 healthy individuals and 307 patients with connective tissue diseases (CTDs). Sera were tested by an automated EIA (COBAS® Core HEp2 ANA EIA; Roche Diagnostics) and IF. Samples were also tested for eight disease-specific antibodies, including antibodies against U1RNP, Sm, SSA/Ro, SSB/La, Scl-70, Jo-1, dsDNA, and centromere. Results: Areas under ROC curves for the EIA were greater than (P = 0.008–0.012) or numerically identical to areas for the IF method for each of six CTDs studied. ROC areas for EIA were 0.98 (95% confidence interval, 0.95–0.99), 0.99 (0.96–1.00), and 0.99 (0.98–1.00) in systemic lupus erythematosus (n = 111), systemic sclerosis (n = 39), and mixed connective tissue disease (n = 33), respectively. For all 258 CTD patients with conditions other than rheumatoid arthritis (RA), the sensitivity and specificity of the IF method at a cutoff dilution of 1:40 were 92% and 65%, respectively, vs 93% and 79% for the EIA at a cutoff of 0.6. For the IF method at a cutoff dilution of 1:160, sensitivity and specificity were 81% and 87%, respectively, vs 84% and 94%, respectively, for the EIA at a cutoff of 0.9. For 207 sera containing at least one of eight disease-specific ANAs, positivities for the EIA and the IF method were 97.1% and 97.6%, respectively, at cutoffs of 0.6 and 1:40 (P = 0.76). Conclusions: An EIA that can be performed by a fully automated instrument distinguishes CTDs (except RA) from healthy individuals with both higher sensitivity and specificity than the IF method when the cutoff index was set at 0.9. Moreover, it can be used to exclude the presence of disease-specific ANAs by setting the cutoff index at 0.6 with almost the same efficacy as the IF method.

Download Full-text